The use of mesenchymal stem cells, obtained through the rigenera® technology, in the treatment of chronic wounds
International Journal of Development Research
The use of mesenchymal stem cells, obtained through the rigenera® technology, in the treatment of chronic wounds
Received 02nd January, 2022; Received in revised form 11th January, 2022; Accepted 23rd February, 2022; Published online 30th March, 2022
Copyright © 2022, Livia Maria Marques Pereira et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The article aimed to highlight the effectiveness of the treatment of difficult-to-heal wounds mediated by mesenchymal stem cells (MSC) obtained through the Rigenera® protocol. Rigenera® technology is a system that allows cell disaggregation that, through mechanical force performed by a device called Rigeneracons, is able to obtain a micrograft containing cell subpopulations (including MSC) that can be used in various interventions. This system has the advantage of eliminating the laboratory steps of MSC preparation. Thus, this work is extremely important, especially for professionals in the medical clinic.
